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Abstract
Lives saved have become a standard metric to express health benefits across interventions and diseases. Recent
estimates of malaria-attributable under-five deaths prevented using the Lives Saved tool (LiST), extrapolating
effectiveness estimates from community-randomized trials of scale-up of insecticide-treated nets (ITNs) in the
1990s, confirm the substantial impact and good cost-effectiveness that ITNs have achieved in high-endemic sub-
Saharan Africa. An even higher cost-effectiveness would likely have been found if the modelling had included the
additional indirect mortality impact of ITNs on preventing deaths from other common child illnesses, to which
malaria contributes as a risk factor.
As conventional ITNs are being replaced by long-lasting insecticidal nets and scale-up is expanded to target
universal coverage for full, all-age populations at risk, enhanced transmission reduction may–above certain
thresholds–enhance the mortality impact beyond that observed in the trials of the 1990s. On the other hand, lives
saved by ITNs might fall if improved malaria case management with artemisinin-based combination therapy averts
the deaths that ITNs would otherwise prevent.
Validation and updating of LiST’s simple assumption of a universal, fixed coverage-to-mortality-reduction ratio will
require enhanced national programme and impact monitoring and evaluation. Key indicators for time trend
analysis include malaria-related mortality from population-based surveys and vital registration, vector control and
treatment coverage from surveys, and parasitologically-confirmed malaria cases and deaths recorded in health
facilities. Indispensable is triangulation with dynamic transmission models, fitted to long-term trend data on vector,
parasite and human populations over successive phases of malaria control and elimination.
Sound, locally optimized budget allocation including on monitoring and evaluation priorities will benefit much if
policy makers and programme planners use planning tools such as LiST - even when predictions are less certain
than often understood. The ultimate success of LiST for supporting malaria prevention may be to prove its linear
predictions less and less relevant.
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Background
Ongoing scale-up of malaria control in an era of leveling
funds for health requires that investments are justified in
terms of their impact and value for money [1]. The Roll
Back Malaria partnership, United Nations (through the
Millennium Development Goals) and World Health
Assembly share a target of reducing malaria deaths by
75% between 2000 and 2015; updated Roll Back Malaria
targets of May 2011 include an even more ambitious
reduction to near-zero malaria deaths by 2015 [2].
Achieving these targets depends critically on the success
of malaria prevention, in particular the provision of
insecticide-treated nets (ITNs) in sub-Saharan Africa, the
region covering 91% of global malaria deaths. Encoura-
gingly, from 2000 to 2010 nine (out of 43) malaria-ende-
mic African countries, as well as 35 (out of 53) Asian
countries with ongoing transmission achieved a more
than 50% reduction in notified malaria cases [2].
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Discussion
Lives saved have become a standard metric to express
these benefits across interventions and diseases [3-8]. The
study by Eisele and colleagues [9] was long-awaited to
confirm the large child health gains realized by malaria
vector control, primarily ITNs. Across 36 African coun-
tries, ITN scale-up is estimated to have reduced malaria
mortality deaths by 24% in year 2010, and to have pre-
vented 842,800 under-five deaths between 2001 and 2010.
These estimates translate into a cost of US$ 2,770 per life
saved or US$ 111 per DALY averted, when compared to
the counterfactual of malaria mortality levels as in 2000,
when ITN coverage was negligible in most countries.
The Lives Saved Tool (a.k.a. LiST) used by Eisele and
colleagues is a suitable mortality projection model, that
has the advantage of considering the impact of malaria
interventions in the context of multiple key child health
interventions, and the full envelope of child deaths from
all causes [10-12].
The authors qualify their malaria impact estimates as
conservative, which is probably correct despite several
uncertainties; in any case the presented cost-effectiveness
ratios are somewhat below those published earlier
[13,14].
First, lives saved were evaluated within an envelope of
malaria-attributable deaths, estimated at 17% of all-cause
deaths in children 1-59 months in the year 2000 [15]. In
the context of estimating child survival gains across multi-
ple disease control programs, this approach avoids the
conceptual problem that lives saved across all interven-
tions would add up to more than the total actual deaths in
the population. However, in reality the impact of malaria
prevention extends beyond direct malaria-attributable
deaths, since malaria acts as a risk factor by causing
chronic anaemia, malnutrition and generally weakening
child health [16,17]. The cluster-randomized ITN trials
that provided the basis for ITN efficacy estimates suggest
that this indirect effect may be at least as large as the
direct effect within malaria-attributable deaths; which is
also why all-cause under-five mortality had–rightly–been
the primary effectiveness measure in these trials [18].
Second, the ITN trials, reaching a near-universal (80-
100%) household possession of ITNs, estimated effective-
ness at a stable 17% reduction in all-cause mortality
among children 1-59 months, or 5.5 per 1,000 child-years
[18]. Re-analysing three of these five trials, Eisele and col-
leagues translated this effectiveness into a fixed 55%
reduction in malaria-attributable deaths in the same age
group [19]. However, the trial sites differed markedly in
baseline malaria transmission intensity (entomological
inoculation rates ranging from < 10 to > 300), all-cause
under-five mortality levels (13 to 52 per 1,000 child-years)
and the proportion of post-neonatal child deaths due to
malaria (36-46% in three trials). It is unclear how all three
of these effectiveness measures could be constant across
the five sites at the same time–and, by extrapolation, some
15 years later across 36 countries, several of which have
since markedly reduced under-five mortality and/or
malaria burden [10,20-23].
A third uncertainty is how ITN effectiveness plays out at
coverage levels different from the near-universal house-
hold possession achieved in the trials. Across the 36 coun-
tries now analysed, household ownership ranged from
3.5% to 94% in 2010 [9]. LiST assumes simple linearity,
but effectiveness in the lowest-coverage countries may be
disproportionally lower if dynamic transmission effects
would only kick in at high coverage [24]. Conversely: Is a
55% reduction in malaria-attributable mortality, without
additional indirect effects on other-cause deaths, a valid
maximum effectiveness for universal net coverage? The
latter is the more important question looking forward, for
two reasons: First, long-lasting insecticidal nets (LLINs)
are replacing conventional ITNs that required retreatment
to remain effective. Second, since 2007, the WHO recom-
mends personal protection for the full population at risk
instead of just children under-five and pregnant women,
resulting in increasing numbers of households owning and
using not just one but several ITNs [2].
Further re-analysis of data from the 1990s trials will not
improve certainty here. More up-to-date reassurance
comes from a recent ecological analysis of household sur-
veys across 22 countries. At ITN ownership levels ran-
ging from 1% to 54% (over 2001-2009), ITN household
ownership reduced all-cause post-neonatal under-five
mortality by 24% (when adjusted for socioeconomic
determinants and coverage of other key child health ser-
vices), more than the 17% in the cluster-randomized
trials [25]. While this survey-based analysis could not
estimate the corresponding absolute mortality reduction,
it suggests that ITN impact might still be fairly stable at
5.5 deaths prevented per 1,000 child-years of protection,
despite the secular trend of falling child mortality.
Enhanced validation of ITN/LLIN effectiveness assump-
tions would require model fitting to individual settings
that scaled-up ITN coverage and measured all-cause and
malaria-attributable mortality trends, in the absence of
change in other child health interventions. This situation
is–fortunately–becoming rarer, as countries scale-up vec-
tor control alongside improved malaria treatment [26,27],
and as part of broader health systems strengthening. A
recent ‘validation’ study by the same authors found that
LiST-predictions fitted child mortality reductions within
the 95% CI of empirical observations across two of the
ITN trials and two observational studies. However, of
these individual sites two had a ‘fit’ 33-35% too high, and
two a ‘fit’ 22-25% too low [28]–suggesting that the malaria
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community remains far from a good understanding of
ITN’s protective efficacy and its determinants across sites.
Validation against recent programme scale-up and
mortality trends will furthermore help to monitor
whether mortality patterns as of 2000 (adjusted only for
population growth) remain the best counterfactual. Even
if ITN usage stopped altogether, malaria-related mortality
may not resurge to levels as high as in 2000, since child
deaths from other major–interacting–causes such as
measles, pneumonia and HIV have fallen since [29,30].
Also is malaria treatment with ACT, by lowering case
fatality rates, reducing the envelope of potentially fatal
malaria deaths that ITNs would prevent [24]. Finally,
indoor residual spraying (IRS) is compounding the
impact of ITNs, although precise estimates of IRS impact
at a regional level are still lacking due to missing data on
population-level coverage from some countries.
Next ambitions should focus on enhancing mortality
measurement, and on better understanding the impact of
vector control in settings of varying endemicity, mortality
and anti-malarial treatment patterns. This requires better
population-based data on the effective coverage of ACT-
based treatment [31] and IRS, and of impact indicators
such as parasite infection and anaemia in children [32]. As
the coverage of parasitological diagnosis (through micro-
scopy and rapid diagnostic tests) is scaled-up, routine sta-
tistics on hospitalizations and in-hospital deaths from
parasitologically confirmed malaria will also become an
increasingly reliable source [2,23,27,33]. For mortality, the
long-term goal for all countries should be to achieve com-
plete and accurate vital registration, classifying causes of
death with the International Coding of Deaths system
version 10 (ICD-10) [34]. Where nation-wide vital regis-
tration is not feasible, sample vital registration or demo-
graphic surveillance using verbal autopsy to establish
causes of death can be a cost-effective interim approach
[35,36].
Synthesizing new insights from improved impact data
requires a very different type of models, simulating inter-
actions between vector, parasite and human populations
over successive phases of malaria control and elimination
[24,37]. Dynamic transmission modelling, fitted in detail
to selected sites, is indispensable to refine assumptions for
simplified health sector planning tools like LiST.
Meanwhile, LiST remains useful to guide short-term
strategic planning and M&E priorities in endemic coun-
tries, notably reinforcing international recommendations
to measure child service coverage and impact indicators
through nationally representative household surveys. The
pending incorporation of ACT-based treatment [31] will
improve LiST’s value for programme budgeting–by illus-
trating the efficiencies expected by shifting allocations
from presumptive (symptom-based) treatment that
inevitably wastes–scarce–ACT courses on patients with
non-malarial fevers, to increased diagnosis and prevention.
Conclusions
Malaria elimination is becoming a tempting goal even
for several currently endemic African countries. But
recent gains remain fragile in view of evolving drug and
insecticide resistance, malaria’s epidemic nature, and the
challenge to sustain programme funding despite many
competing development priorities that are all (very)
cost-effective [2]. Sound, locally optimized budget allo-
cations will benefit much if policy makers and pro-
gramme planners use simple tools as LiST–even when
predictions are much less certain than often understood.
The ultimate success of LiST for supporting malaria
prevention may be to prove its linear predictions less
and less relevant.
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